当前位置： SCI文献检索 > POSTGRADUATE MEDICINE期刊下所有文献 > Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.

Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.

Abstract：

OBJECTIVE:To evaluate the efficacy and safety of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. MATERIALS AND METHODS:A 16-week, randomized, double-blind, placebo-controlled, multinational study evaluating colesevelam in participants with primary hyperlipidemia (low-density lipoprotein cholesterol [LDL-C] level ≥ 100 mg/dL) and prediabetes (fasting plasma glucose level ≥ 110 to ≤ 125 mg/dL, or 2-hour postload glucose level ≥ 140 to < 200 mg/dL during an oral glucose tolerance test) was conducted between January 14, 2008 and April 3, 2009. Participants were randomized 1:1 to colesevelam 3.75 g/day or placebo. The primary efficacy endpoint was mean change from baseline in LDL-C level with colesevelam compared with placebo. Participants who self-identified as Hispanic during enrollment were included in this exploratory analysis evaluating the efficacy of colesevelam in Hispanics with primary hyperlipidemia and prediabetes. RESULTS:From a total of 216 subjects with primary hyperlipidemia and prediabetes, 153 Hispanics were included in this post hoc analysis; 77 subjects were randomized to colesevelam and 76 subjects were randomized to placebo. At week 16, LDL-C levels were significantly reduced with colesevelam compared with placebo (mean treatment difference, -19.4%; P < 0.0001). Achievement of LDL-C level < 100 mg/dL was more frequent with colesevelam than with placebo (27% vs 11%; P = 0.002). In addition, significant mean reductions in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B levels (P ≤ 0.0002 for all), and a significant median increase in triglyceride levels (P = 0.003), were seen with colesevelam compared with placebo. At study end, there was a significant mean reduction in glycated hemoglobin levels and median reduction in fasting plasma glucose levels with colesevelam compared with placebo (P ≤ 0.02 for both). A fasting plasma glucose level < 100 mg/dL was achieved in 44% of colesevelam recipients compared with 23% of placebo recipients (P < 0.05). Overall, colesevelam was well tolerated. CONCLUSION:Colesevelam may be a treatment option for Hispanic subjects with primary hyperlipidemia and prediabetes, mainly to reduce LDL-C levels, with added beneficial effect on glucose levels. TRIAL REGISTRATION:www.ClinicalTrials.gov identifier NCT00570739.

journal_name

Postgrad Med

journal_title

Postgraduate medicine

authors

Rosenstock J,Hernandez-Triana E,Handelsman Y,Misir S,Jones MR

doi

10.3810/pgm.2012.07.2564

subject

Has Abstract

pub_date

2012-07-01 00:00:00

pages

14-20

issue

eissn

0032-5481

issn

1941-9260

journal_volume

124

pub_type

杂志文章,随机对照试验

在线工具

Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes.